99614-64-9,
9-Methyl-3-methylene-2,3-dihydro-1H-carbazol-4(9H)-one,
1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one,
UNII-098F00IT8F,
9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one,
1,2,3,9-Tetrahydro-9-methtyl-3-methylene-4H-carbazol-4-one,
Ondansetron impurity D (PhEur),
098F00IT8F,
9-methyl-3-methylidene-1,2-dihydrocarbazol-4-one,
Ondansetron related compound D [USP],
Ondansetron Related Compound D (USP),
4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-methylene-,
W-204255,
Ondansetron related compound D,
Ondansetron related compound D RS [USP],
SCHEMBL3549753,
CTK5I0565,
DTXSID80244167,
AGQJDIDJKSFVTC-UHFFFAOYSA-N,
1,2,3,4-Tetrahydro-9-methyl-3-methylene-9H-carbazol-4-one,
Ondansetron hydrochloride dihydrate specified impurity D [EP],
6989AC,
ANW-72988,
CT-292,
STL450906,
ZINC21301192,
AKOS015914839,
AJ-78379,
BC220552,
ondansetron hcl ep impurity-d (usp rc d),
AB0102882,
AX8052768,
TC-161733,
TL8006072,
1,2,3,9-Tetrahydro-9-methtyl-3-methylene,
4CH-024340,
FT-0653973,
ST24045872,
I14-7383,
1,2,3,9-Tetrahydro-3-methylene-9-methyl-4H-carbazol-4-one,
1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazole-4-one,
4h-carbazol-4-one,1,2,3,9-tetrahydro-9-methyl-3-methylene-,
9-methyl-3-methylidene-1,2,3,9-tetrahydro-4H-carbazol-4-one,
Ondansetron impurity D, European Pharmacopoeia (EP) Reference Standard,
1,2,3,9-Tetrahydro-9-methtyl-3-methylene-4H-carbazol-4-one(ondansetron intermediate),
9-Methyl-1,2,3,9-tetrahydro-4H-carbazol-4-one, pharmaceutical impurity standard,
Ondansetron Related Compound C, United States Pharmacopeia (USP) Reference Standard,
Ondansetron Related Compound D, United States Pharmacopeia (USP) Reference Standard,
9-Methyl-3-methylene-1,2,3,9-tetrahydro-4H-carbazol-4-one, >=95.0% (HPLC), pharmaceutical impurity standard,
Ondansetron Impurity D,
C14H13NO,
CS-O-31137,
CID11790505,
3,9-dimethyl-2,3-dihydro-1H-carbazol-4-one,
1,2,3,9-Tetrahydro-9-methtyl-3-methylene-4H-carbazol-4-one?,